Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Open accessThe DOI matches its Crossref record; 134 of the 141 references it cites were found in a registry or an index; 90 of the 190 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients with diabetes that has become available since the past reviews of this subject by the American Diabetes Association and The Endocrine Society and to provide guidance about how this new information should be incorporated into clinical practice. PARTICIPANTS: Five members of the American Diabetes Association and five members of The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair, who is a member of both, to participate in a planning conference call and a 2-day meeting that was also attended by staff from both organizations. Subsequent communications took place via e-mail and phone calls. The writing group consisted of those invitees who participated in the writing of the manuscript. The workgroup meeting was supported by educational grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes Association from Sanofi. The sponsors had no input into the development of or content of the report. EVIDENCE: The writing group considered data from recent clinical trials and other studies to update the prior workgroup report. Unpublished data were not used. Expert opinion was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved by group discussion during conference calls and face-to-face meetings, as well as by iterative revisions of the written document. The document was reviewed and approved by the American Diabetes Association's Professional Practice Committee in October 2012 and approved by the Executive Committee of the Board of Directors in November 2012 and was reviewed and approved by The Endocrine Society's Clinical Affairs Core Committee in October 2012 and by Council in November 2012. CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
Overview
CoChat Summary
TL;DR
This ADA/Endocrine Society workgroup report updates definitions, risks, and prevention strategies for hypoglycemia in diabetes, with a strong emphasis on avoiding severe episodes and hypoglycemia unawareness. It argues for individualized glycemic targets, better monitoring and education, and further research on outcomes, measurement, and new therapies.
Key findings
- The workgroup defines iatrogenic hypoglycemia as all episodes of abnormally low plasma glucose that expose the person to potential harm, and recommends an alert value of ≤70 mg/dL (≤3.9 mmol/L) for patients at risk; it also classifies episodes as severe, documented symptomatic, asymptomatic, probable symptomatic, or pseudo-hypoglycemia.
- Severe hypoglycemia rates reported in the paper ranged from 115 to 320 per 100 patient-years in type 1 diabetes and 35 to 70 per 100 patient-years in type 2 diabetes; because type 2 diabetes is more common, most hypoglycemia episodes occur in people with type 2 diabetes.
- In ACCORD, intensive glycemic control produced threefold higher hypoglycemia and a 20% increase in mortality; post hoc analyses in ACCORD found severe hypoglycemia had a hazard ratio of 1.41 (95% CI 1.03–1.93) for death.
- In hospitalized patients, one retrospective study found 10.5% of 31,970 general-ward admissions had at least one hypoglycemic episode (≤70 mg/dL), and severe hypoglycemia (≤50 mg/dL) was associated with increased length of stay and greater odds of inpatient death and death within 1 year of discharge.
Methods
- This is a workgroup report/consensus document, not an experimental study; five ADA and five Endocrine Society experts were invited, held a planning call and a 2-day meeting, and developed the manuscript through discussion and iterative revisions.
- The group reviewed recent clinical trials and other studies published since the prior reports; unpublished data were not used, and some conclusions relied on expert opinion.
- Consensus was reached by group discussion and was reviewed/approved by both organizations’ committees in October and November 2012.
Limitations
- The paper states that unpublished data were not used, and that expert opinion was used to develop some conclusions.
- The text makes evident that some evidence is observational, post hoc, or limited by small studies, so causal inference is uncertain in several areas (e.g., mortality, cognition); this is an inference from the paper’s cited evidence, not a limitation explicitly stated in one place.
- The paper explicitly notes gaps in knowledge on hypoglycemia outcomes, mechanisms, and prevention, indicating that several recommendations are based on incomplete evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 5 Not valid · 33 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“There is convincing evidence that formal training programs that teach patients to replace insulin “physiologically” by giving background and mealtime/correction doses of insulin can reduce the risk of severe hypoglycemia.”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > What strategies are known to prevent hypoglycemia, and what are the clinical recommendations for those at risk for hypoglycemia? > Patient education
What the sources say
- Supportedcites [100] Mühlhauser, 2002, Patient education—evaluation of a complex intervention, Diabetologia source
The Modelling section describes a structured programme teaching patients to adjust insulin doses, using NPH insulin twice daily and regular insulin before meals. The Long-term implementation section reports decreased rates of severe hypoglycaemia in patients with Type I diabetes and says several prospective studies observed that reduction. The paper supports that such programmes can reduce the risk, although not every evaluation found a reduction. (LLM, conf=0.90)
- Partly supportedcites [101] Bott, 1997, Intensified insulin therapy and the risk of severe hypoglycaemia, Diabetologia sourceExperimental — accuracy not yet measured
The Subjects and methods passage describes structured training in background and mealtime insulin dosing, with patients adjusting doses for glucose and carbohydrate intake. The Results and Discussion report fewer severe hypoglycaemic episodes after the programme, but describe the reduction as an association; they do not establish that training itself caused it. The claim’s description of this as convincing evidence that the programmes can reduce risk is therefore stronger than the paper’s finding. (LLM, conf=0.84)
- Supportedcites [102] Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study, Diabetologia source
The Subjects and methods section describes a structured course teaching background insulin injections and meal-by-meal dose adjustments based on blood glucose and carbohydrate intake. The Abstract reports that severe hypoglycaemia fell from 0.37 to 0.14 events per patient per year after training among people with type 1 diabetes. (LLM, conf=0.92)
- Disputedcites [103] DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ sourceExperimental — accuracy not yet measured
The skills course section describes training patients to adjust insulin to their meals. But the paper reports that severe hypoglycaemia remained unchanged; the Discussion says there was no significant increase, not a reduction in risk. The claimed risk reduction is therefore contrary to the reported finding. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [104] McIntyre, 2010, Dose adjustment for normal eating (DAFNE)—an audit of outcomes in Australia, Med J Aust source
- Partly supportedcites [105] Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (pages not provided) report fewer severe hypoglycemia episodes after DAFNE, a structured education program for adults with type 1 diabetes. The paper describes adjusting insulin to carbohydrate intake, but does not specify the claimed background and mealtime/correction-dose teaching. Its evidence is also a retrospective audit based on self-reported hypoglycemia, which qualifies the claim of ‘convincing evidence.’ (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12)”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion states that after an episode of hypoglycemia, the authors found elevated glycemic thresholds for neurogenic and neuroglycopenic symptoms, including in patients with IDDM in the present study. Its terminology indicates that an elevated threshold means symptoms occur at a lower plasma glucose concentration. The Results also report reduced symptom responses after antecedent hypoglycemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In critical care units, where the accuracy of POC meters is particularly crucial, their performance may be compromised by medications (vasopressors, acetaminophen), treatments (oxygen), and clinical states (hypotension, anemia) (17).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported? > The challenge of measuring glucose accurately
What the sources say
- Partly supportedcites [17] Klonoff, 2011, Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Section 1.1 Evidence says supplemental oxygen can cause falsely low readings with glucose-oxidase meters and identifies acetaminophen, pressor use, and hypotension as potential concerns for POC testing in critically ill patients. It also reports an accuracy discrepancy among patients with hypotension or pressor treatment. The cited passages do not address anemia as a cause of compromised meter performance. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A single threshold value for plasma glucose concentration that defines hypoglycemia in diabetes cannot be assigned because glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12) and to higher plasma glucose concentrations in patients with poorly controlled diabetes and infrequent hypoglycemia”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion (p. 823) reports that antecedent hypoglycemia changes the glycemic threshold for symptoms in patients with insulin-dependent diabetes. The Discussion also reports symptoms at higher plasma glucose concentrations in patients with poorly or moderately controlled diabetes. Together, these findings support the claim that no single symptom-based plasma glucose threshold applies across these circumstances. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
- Not checked — no full text of the sourcecites [13] Boyle, 1988, Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hypoglycemia puts patients at risk for injury and death.”
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
“There is no doubt that hypoglycemia can be fatal (26).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Supportedcites [26] Cryer, 2011, Death during intensive glycemic therapy of diabetes: mechanisms and implications, Am J Med source
In the main text (page unavailable), Cryer states that iatrogenic hypoglycemia causes recurrent morbidity in people with diabetes and is sometimes fatal. This supports the broad claim that hypoglycemia puts these patients at risk of harm and death. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
76 more claims · 43 with their cited sources checked
Create a free account to see all 104 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial hyperglycemia and resultant compensatory hyperinsulinemia from high dietary glycemic load can lower plasma glucose to concentrations that compromise brain glucose, w70 mg/dL (3.8 mmol/L) (36), triggering the secretion of autonomic counterregulatory hormones such as adrenaline, cortisol, glucagon, and growth hormone (37).”
From High glycemic index diet as a risk factor for depression: analyses from the Women’s Health Initiative (2015) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103-105).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recurrent hypoglycaemia results in an increased likelihood of hypoglycaemia unawareness and subsequent severe hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that triggers the counter-regulatory responses to return to euglycaemia.106”
From Type 1 diabetes (2018) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoglycemia is a frequent and dangerous complication of diabetes (1), causing changes in physiological parameters (2,3).”
From Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Individualized glucose targets, patient education, nutrition intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (94).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [94]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Deakin T McShane CE Cade JE Williams RD Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003417 15846663”
Cited work 10.1002/14651858.cd003417.pub2 · retracted 2015-06-30 · notice 10.1002/14651858.cd003417.pub3 · this paper published 2013-04-13
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In VADT, a recent severe hypoglycemic event was the strongest independent predictor of death at 90 days (3).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 2×
“event of troublesome hypoglycemia (96).”
BackgroundIntensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Research works printed but not linked: 2
- Reno, 2011, Deaths due to severe hypoglycemia are exacerbated by diabetes and ameliorated by hypoglycemic pre-conditioning (Abstract), Diabetes, 60, A81
- Aubert, 1995, Diabetes-Related Hospitalization and Hospital Utilization
Cited by
Items 801–900 of 1,392
Inpatient glucose management programme in the Asian healthcare setting
Swee, D. S., Ang, L. C., Heng, W. M., Lee, D. X.-Y., Xin, X., Kumaran, S. S., Wong, K. S., Bee, Y. M., Goh, S., & Teh, M. M. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12985 · Cited by 8
de Wit, M., Rondags, S. M. P. A., van Tulder, M. W., Snoek, F. J., & Bosmans, J. E. (2017) · Diabetic Medicine · doi:10.1111/dme.13548 · Cited by 8
Lepore, G., Bonfanti, R., Bozzetto, L., Blasi, V. D., Girelli, A., Grassi, G., Iafusco, D., Laviola, L., Rabbone, I., Schiaffini, R., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.12.001 · Cited by 12
Haluzík, M., Kretowski, A. J., Strojek, K., Czupryniak, L., Janež, A., Kempler, P., Anděl, M., Tankova, T. I., Boyanov, M., Duvnjak, L. S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0388-2 · Cited by 9
“A patient-centered approach not only includes close direct communication, but also patientreported outcomes, structured and individual patient education, individualized treatment, and self-monitoring and self-management of the DM [10].”
BackgroundCorchuelo, J. C., Guerrero‐Pérez, F., de la Jordana, P. G.-S., & Pérez-Maraver, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.06.013 · Cited by 13
“Cirrosis hepática, n (%) 5 (3,4) 0 5 (4,2) NS”
InfluentialThrasher, J. R., Polsky, S., Hovsepian, L., NOWOTNY, I. K., Pierre, S., Fer, B. B. D., Bhargava, A., Mukherjee, B., & Garg, S. K. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0446 · Cited by 9
“…designed study evaluating the insulin lispro biosimilar/follow-on product SAR342434 that Due to failure-to-correct hyperglycemia a 18.59 – 10.16 [14] 19.06 – 9.41 [12] Occlusion occurred or was suspected b 19.58 – 9.81 [20] 18.12 – 9.45 [15] Due to pump malfunction 29.00 – NC [1] [0] Based on…”
InfluentialWeiner, M., Cummins, J., Raji, A., Ofner, S., Iglay, K., Teal, E. Y., Li, X., Engel, S. S., Knapp, K., Rajpathak, S. N., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1717451 · Cited by 8
“0001 Coronary artery disease 51 (8) 60 (9) 77 (12) 141 (21) 216 (32) <.”
BackgroundInfluentialAlmomani, H. Y., Pascual, C., Al-Azzam, S. I., & Ahmadi, K. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.07.012 · Cited by 8
Gradišer, M., Bilić-Čurčić, I., Djindjić, B., & Berković, M. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0130-2 · Cited by 8
Montt‐Blanchard, D., Dubois‐Camacho, K., Costa‐Cordella, S., & Sánchez, R. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1013877 · Cited by 7
Surrati, A. M. Q., Alanazi, A. A., Bukhari, S., & Alfadhli, E. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1239524 · Cited by 11
Penaforte-Saboia, J. G., Couri, C. E. B., Fernandes, V. O., Montenegro, A. P. D. R., Batista, L. A. D. A., Zajdenverg, L., Negrato, C. A., Malmegrim, K. C. R., Moraes, D. A., Dias, J. B. E., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00747 · Cited by 8
Contreras, M., Mesa, A., Pueyo, I., Claro, M. I., Milad, C., Viñals, C., Roca, D., Granados, M., Giménez, M., & Conget, I. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108560 · Cited by 7
Smartwatches for non‐invasive hypoglycaemia detection during cognitive and psychomotor stress
Maritsch, M., Föll, S., Lehmann, V. F., Styger, N., Bérubé, C., Kraus, M., Feuerriegel, S., Kowatsch, T., Züger, T., Fleisch, E., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15402 · Cited by 8
Glucose Control During Labour and Delivery in Type 1 Diabetes – An Update on Current Evidence
Ringholm, L., Søholm, J. C., Pedersen, B. W., Clausen, T. D., Damm, P., & Mathiesen, E. R. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01563-1 · Cited by 8
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
Kalra, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.155407 · Cited by 8
Lipowsky, C., Sze, L., Krull, I., & Brändle, M. (2015) · Diabetes Therapy · doi:10.1007/s13300-014-0093-8 · Cited by 7
“other resuscitative actions [12].”
Lundershausen, R., Müller, S., Hashim, M., Kienhöfer, J., Kipper, S., & Wilke, T. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0636-3961 · Cited by 7
“A secondary objective was to evaluate changes in key clinical parameters, including glycated hemoglobin (HbA1c), body mass index (BMI), and SBP, as well as safety and tolerability, including adverse drug reactions and the incidence of non-severe/severe hypoglycemic episodes (defined in accordance with the American Dia…”
BackgroundThe prescription rates of glucagon for hypoglycemia by pediatricians and physicians are low in Japan
Matsumoto, M., Awano, H., Hirota, Y., Nagai, M., Bo, R., Matsuoka, A., Hamaguchi, T., Takeuchi, T., Nakagawa, Y., Ogawa, W., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1793-z · Cited by 8
Andreano, A., Bosio, M., & Russo, A. G. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0546-1 · Cited by 8
Savoury cracker development for blood glucose control and management
Qi, X., Ta, M. N., & Tester, R. F. (2020) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2020.100249 · Cited by 8
Pieber, T. R., BAJAJ, H. S., Heller, S. R., Jia, T., Khunti, K., Klonoff, D. C., Ladelund, S., Leiter, L. A., Wagner, L., & Philis‐Tsimikas, A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14564 · Cited by 7
Self-citationGameil, M. A., Marzouk, R. E., El-Sebaie, A. H., & Eldeeb, A. A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102606 · Cited by 8
Hoffman, E. G., D’Souza, N. C., Aiken, J., ATHERLEY, S. C., Liggins, R., & Riddell, M. C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15002 · Cited by 9
Zeitoun, M. H., Reheem, A. A. A., Kharboush, I. F., Sheshtawy, H. A., Assad, D. H., & Feky, A. Y. E. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.03.002 · Cited by 12
Mesa, A., Beneyto, A., José, J., Viaplana, J., Bondía, J., Vehí, J., Conget, I., & Giménez, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110956 · Cited by 7
Palliative and end of life care for people with diabetes: a topical issue
Dunning, T. L., Savage, S., Duggan, N., & Martin, P. (2014) · Diabetes Management · doi:10.2217/dmt.14.33 · Cited by 7
Ogawa, S., Nako, K., Okamura, M., Senda, M., Sakamoto, T., & Ito, S. (2013) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2013.34037 · Cited by 7
Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia
Ross, S. A., Caballero, A. E., Prato, S. D., Gallwitz, B., Lewis-D’Agostino, D. J., Bailes, Z., Thiemann, S., Patel, S. D., Woerle, H., & von Eynatten, M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1238280 · Cited by 7
Hypoglycaemia manifestations and recurrent events: L essons from the SAVOR‐TIMI 53 outcome study
Cahn, A., Mosenzon, O., Bhatt, D. L., Leibowitz, G., Yanuv, I., Rozenberg, A., Iqbal, N., Hirshberg, B., Stahre, C., Im, K., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12903 · Cited by 7
“Retrospective enquiry of the precipitants of the event as well as consideration of means to avoid future events should be encouraged after a hypoglycaemic event, particularly a major event.(5,8,9) Approximately half of the participants reported no known identifiable precipitant to any hypoglycaemic event and 40% did n…”
BackgroundResultKim, J. L., Gamma, E. F. L., Estabrook, T., Kudrick, N., & Nankova, B. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172789 · Cited by 9
“Profound or recurrent hypoglycemia (RH) leads to increased morbidity and mortality with acute and chronic symptomatology and is a major public health problem in diabetic patients ([1], [2], [3]).”
BackgroundKuniß, N., Müller, U. A., Kloos, C., Wolf, G., & Kramer, G. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-112862 · Cited by 8
Kesavadev, J., Pillai, P. B. S., Shankar, A., Krishnan, G., & Jothydev, S. (2017) · Endocrine Connections · doi:10.1530/ec-17-0100 · Cited by 7
Allen, A., Welch, L. S., Kirkland, K., Trout, D. B., & Baron, S. (2017) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001181 · Cited by 8
“There are two groups of employed patients specifically targeted for this project: those patients with elevated HbA1C, and those patients demonstrating symptomatic or serious hypoglycemia, with ‘‘serious’’ defined as a situation requiring help from a third party and ‘‘symptomatic’’ defined as an event during which typi…”
BackgroundGlycemic Control of People With Type 1 Diabetes Based on Probabilistic Constraints
Nandi, S., & Singh, T. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2869365 · Cited by 10
“According to a joint consensus statement from the ADA and the Endocrine Society regarding hypoglycemia and diabetes [21], the threshold for hypoglycemia (Glb ) should be 70 mg dL .”
BackgroundShariff, A., Sridhar, S. B., Bittar, H., Hamad, A., Ahmed, R. M., & Kadour, G. (2019) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_18_58 · Cited by 9
Individualizing Glycemic Control in the Critically Ill
Murphy, C. V., Saliba, L., MacDermott, J., Soe, K. K., & Dungan, K. M. (2019) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000288 · Cited by 9
Mu, C., Xing, Q., & Zhai, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229562 · Cited by 9
“Severe hypoglycemia, at which point the patient is not able to independently treat themselves, causes mental confusion or coma, and even death if not treated in time[4].”
BackgroundInhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
Belfort‐DeAguiar, R., Naik, S., Hwang, J. J., Szepietowska, B., & Sherwin, R. S. (2015) · Diabetes Care · doi:10.2337/dc14-2472 · Cited by 8
Inagaki, N., Sheu, W. H., Owens, D. R., Crowe, S., Bhandari, A., Gong, Y., & Patel, S. D. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.002 · Cited by 7
“There is growing recognition that hypoglycemia in individuals with T2DM is not a trivial complication, and that preventing or minimizing hypoglycemic events may be as important as achieving tight glycemic control in vulnerable individuals (Seaquist et al., 2013; Slomski, 2013).”
BackgroundThe optimal blood glucose level for critically ill adult patients
Lv, S., Ross, P., & Tori, K. E. (2017) · Nursing in Critical Care · doi:10.1111/nicc.12285 · Cited by 7
Role of the Diabetes Educator in Inpatient Diabetes Management
American Association of Diabetes Educators (2018) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721718754817 · Cited by 10
Golicki, D. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000435 · Cited by 7
Fusi, J., Scarfò, G., Silvestro, R., & Franzoni, F. (2025) · Nutrients · doi:10.3390/nu17111779 · Cited by 10
“…physiological mechanisms in response to the post-prandial hyper-glycemia: particularly, a sudden insulin release causes a drastic decrease in plasma glucose concentration around ∼ 3.8 mmol/L [37], followed by the secretion of counterregulatory hormones, including adrenalin and noradrenalin [38,39].”
InfluentialWagner, R. J., Füchtenbusch, M., Hummel, M., Miszon, M., Pfützner, A., Tan, S., & Wiesner, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113047 · Cited by 8
Carbohydrate metabolism in chronic renal disease
Adamczak, M., Ritz, E., & Więcek, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00005-7 · Cited by 9
Clark, J. E., Boehmer, K. R., Breslin, M., Haider, S., Pasciak, W., Gravholt, D., SANCHEZ, B. B. M., Hartasanchez, S. A., Kawkgi, O. M. E., Montori, V. M., et al. (2021) · Pilot and Feasibility Studies · doi:10.1186/s40814-021-00935-8 · Cited by 7
Chin, R., Nagaoka, S., Nakasawa, H., Tanaka, Y., & Inagaki, N. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13932 · Cited by 7
Kostopoulou, E., Andreopoulou, O., Daskalaki, S., Kotanidou, E. P., Vakka, A., Galli‐Τsinopoulou, A., Spiliotis, B. E., Gonder-Frederick, L. A., & Fouzas, S. (2023) · Children · doi:10.3390/children10091458 · Cited by 7
“In its more severe form, it may result in seizures, coma, or even death [2].”
BackgroundCerebral traumatic injury and glucose metabolism: a scoping review
Quintana-Pájaro, L. D. J., Padilla-Zambrano, H., Ramos-Villegas, Y., López-Cepeda, D., Andrade-López, A., Hoz, S. S., Moscote‐Salazar, L. R., Joaquim, A. F., Florez-Perdomo, W. A., & Janjua, T. M. (2023) · The Egyptian Journal of Neurosurgery : the official publication of the Egyptian Society of Neurological Surgeons/Egyptian journal of neurosurgery · doi:10.1186/s41984-023-00255-4 · Cited by 7
“The American Diabetes Association defines hypoglycemia as a blood glucose level of 70 mg/dL [33, 34].”
BackgroundBrod, M. I., Galstyan, G. R., Unnikrishnan, A., Harman‐Boehm, I., Prusty, V., Lavalle-Gonzalez, F. J., McGill, M. J., Murphy, A., & Puchulu, F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0164-0 · Cited by 7
“The current consensus statement from a working group of the American Diabetes Association and the Endocrine Society describes a number of strategies that are known to help prevent hypoglycemia [4].”
BackgroundAvailable at a flash: a new way to check glucose
Thabit, H., Bally, L., & Hovorka, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31582-3 · Cited by 7
Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality
Bonaventura, A., Gallo, F., Carbone, F., Liberale, L., Maggi, D. C., Sacchi, G., Dallegri, F., Montecucco, F., & Cordera, R. (2018) · Acta Diabetologica · doi:10.1007/s00592-017-1094-7 · Cited by 6
Rosenzweig, J. L., Conlin, P. R., Gonzalvo, J. D., Kutler, S. B., Maruthur, N. M., Solis, P., Vijan, S. S., Wallia, A., & Wright, R. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz250 · Cited by 6
Self-citationMathieu, C., Weisnagel, S. J., Stella, P., Bruhwyler, J., & Alexandre, K. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00749-1 · Cited by 6
McCarthy, O. M., Pitt, J. P., Churm, R., Dunseath, G. J., Jones, C., Bally, L., Nakas, C. T., Deere, R., Eckstein, M. L., Bain, S. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001577 · Cited by 8
Lambert-Obry, V., Lafrance, J., Savoie, M., & Lachaîne, J. (2022) · JMIR Research Protocols · doi:10.2196/35461 · Cited by 6
Aravind, S. R., Singh, K. P., Aquitania, G. P., Mogylnytska, L., Zalevskaya, A. G., Matyjaszek‐Matuszek, B., Wernicke‐Panten, K., Nguyên‐Pascal, M., Pierre, S., Rotthaeuser, B., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01255-7 · Cited by 7
External validation and clinical application of the predictive model for severe hypoglycemia
Yun, J., Han, K., Choi, S.-Y., Cha, S., Ahn, Y., & Ko, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1006470 · Cited by 8
Kladov, D. E., Berikov, V., Semenova, J. F., & Klimontov, V. V. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101454 · Cited by 6
“An episode of NH may be a cause of sleep disturbances and morning headache, chronic fatigue, and mood changes; it is also associated with cardiac arrhythmias, resulting in “death-in-bed syndrome” [8,9].”
BackgroundЛаптев, Д. Н. (2014) · Problems of Endocrinology · doi:10.14341/probl201460224-30 · Cited by 5
“Данное значение было выбрано, исходя из рекомендаций рабочей группы Американской Диабетической Ассоциации [11].”
Driving and diabetes mellitus in the Gulf Cooperation Council countries: Call for action
Hassoun, A. A. K., Abdella, N., Arouj, M. A., Awadi, F. A., Futaisi, A. A., Lamki, M. A., Madani, A. A., Saber, F. A., Nakhi, A. B., Beshyah, S., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.08.002 · Cited by 6
“[5] Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.”
BackgroundInfluentialMurakami, T., Shinoto, Y., Yonemitsu, S., Muro, S., Oki, S., Koga, Y., Goto, Y., & Kaneda, D. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.238.311 · Cited by 7
Coated pellets with delayed-release glucose for prevention of hypoglycemic episodes
Sabadková, D., Franc, A., Muselík, J., et al. (2016) · Acta Pharmaceutica · doi:10.1515/acph-2016-0017 · Cited by 6
Farahani, P., Khan, S., Oatway, M. A., & Dziarmaga, A. (2015) · PubMed · Cited by 6
Fat and protein counting in type 1 diabetes
Hibbert‐Jones, E. (2016) · Practical Diabetes · doi:10.1002/pdi.2049 · Cited by 10
Hypoglycemia in Diabetes: Challenges and Opportunities in Care
Kreider, K. E., Padilla, B. I., & Pereira, K. C. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.08.032 · Cited by 6
Esteves, C., Neves, C., Sa, J., & Carvalho, D. M. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3363-0 · Cited by 6
“Introduction Hypoglycaemia is a major barrier to the achievement of optimal glycaemic control in diabetes (DM) [1, 2].”
BackgroundLuu, Q. F., Villareal, C. J., Fritschi, C., Monson, R. S., Oberholzer, J., & Danielson, K. K. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.002 · Cited by 8
Field, B. C. T., Nayar, R., Kilvert, A., Baxter, M., Hickey, J., Cummings, M. H., & Bain, S. C. (2018) · Diabetic Medicine · doi:10.1111/dme.13670 · Cited by 7
Association of Tramadol and Hypoglycemia in Diabetic Asians
Li, S.-Y., Chen, H., Lin, C., Yeh, S.-Y., & Kao, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7110380 · Cited by 6
“Tramadol is one of the medications prescribed by the American Diabetes Association for treating painful diabetic peripheral neuropathy [8].”
BackgroundInfluentialLuo, Y., Ni, W.-J., Ding, B., Xu, X., Ye, L., Ma, J., & Zhu, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0545-7 · Cited by 8
“Hypoglycemia, which is the primary potential complication of antidiabetes medicines, is strongly associated with an increased risk of cardiovascular events and death [25].”
BackgroundCanbolat, Ö., Kapucu, S., & Kılıçkaya, O. (2019) · Critical Care Nurse · doi:10.4037/ccn2019431 · Cited by 7
Philis‐Tsimikas, A., Lane, W. S., Pedersen‐Bjergaard, U., Wysham, C., Bardtrum, L., Østoft, S. H., & Heller, S. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13954 · Cited by 7
“Defined as requiring third-party assistance.(23) Defined as symptoms of hypoglycaemia, blood glucose level ≤70 mg/dL, or both.”
BackgroundSelf-citationLiew, A., Holmes‐Truscott, E., Flatt, A. J., Bennett, D., Crookston, R. M., Pimkova, M., Birtles, L., Casey, J., Pernet, A., Wood, R., et al. (2020) · Islets · doi:10.1080/19382014.2020.1736740 · Cited by 6
“Demographic and clinical data included HbA1 c and number of self-reported severe hypoglycemia events over the preceding 12 months.(36) A comprehensive set of psychological characteristics and outcomes were assessed, as described below.”
Wolnik, B., de Wiza, D., Szczepanik, T., Syta, A., & Klupa, T. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8751348 · Cited by 5
“Hypoglycaemia is considered to be the major barrier to achieving optimal control with insulin treatment of T2DM [1].”
Hypoglycemia in the emergency, is there any effect on endothelial and diastolic functions?
Akhan, O., & Ardahanlı, İ. (2021) · Echocardiography · doi:10.1111/echo.14988 · Cited by 9
Diabetes Mellitus in Older Women
Lodhi, T. I. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.06.003 · Cited by 9
Gourdy, P., Bonadonna, R. C., Freemantle, N., Mauricio, D., Müller‐Wieland, D., Bigot, G., Mauquoi, C., Ciocca, A., & Bonnemaire, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01179-8 · Cited by 7
“Severe hypoglycaemia was defined as any event requiring assistance from another person to actively administer carbohydrates or glucagon or to take other corrective actions [32].”
BackgroundBallou, C., Barton, F. B., Payne, E. H., Berney, T., Villard, J., Meier, R. P. H., Baidal, D. A., Alejandro, R., Robien, M. A., Eggerman, T. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110544 · Cited by 9
Culley, C. M., Perera, S., Marcum, Z. A., Kane‐Gill, S. L., & Handler, S. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13648 · Cited by 6
Franchin, A., Maran, A., Bruttomesso, D., Corradin, M. L., Rossi, F., Zanatta, F., Barbato, G. M., Sicolo, N., & Manzato, E. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-017-0728-5 · Cited by 6
Rokamp, K. Z., Olsen, N. V., Færch, L., Kristensen, P. L., Thorsteinsson, B., & Pedersen‐Bjergaard, U. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02739 · Cited by 8
The cost of hypoglycemia associated with type 2 diabetes mellitus in taiwan
Strizek, A., Chang, C.-J., Furnback, W., Wang, B., Lebrec, J., & Lew, T. (2019) · Value in Health Regional Issues · doi:10.1016/j.vhri.2019.01.002 · Cited by 5
KAMIMOTO, J. L. J., Li, Z., Gal, R. L., Castle, J. R., Doyle, F. J., Jacobs, P. G., Martin, C. K., Beck, R. W., Calhoun, P. M., Riddell, M. C., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae115 · Cited by 6
Sicras‐Mainar, A., & Navarro‐Artieda, R. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.1.74 · Cited by 6
Assessing Rates of Hypoglycemia as an End Point in Clinical Trials
Muchmore, D. B., Heinemann, L., Tamborlane, W. V., Wu, X., & Fleming, A. (2015) · Diabetes Care · doi:10.2337/dc15-0808 · Cited by 5
“The American Diabetes Association (ADA) recently convened a working group to assess the impact of hypoglycemia and to provide guidance about how this information should be used in practice (1), but the methods used to assess hypoglycemia in clinical trials have received less attention.”
BackgroundMethodInfluentialKramer, G., Kuniß, N., Jörgens, V., Lehmann, T., Muller, N., Lorkowski, S., Wolf, G., Müller, U. A., & Kloos, C. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.002 · Cited by 8
Cathbert, T. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.029 · Cited by 6
Cardoso, C., & de Arellano, A. R. (2016) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000653 · Cited by 5
“However, insulin therapy is frequently associated with hypoglycemic episodes [5], which imply a significant economic and social impact [6].”
BackgroundHypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study
Alão, S., Conceição, J., Dores, J. M., Santos, L. D. C., Araújo, F., de Pape, E. A., Reis, M., Chipepo, Á., Nascimento, E., Baptista, A., et al. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00114-3 · Cited by 4
“Again, this denotes the frailty of patients at higher risk of hypoglycemia and the importance of adopting strategies and therapies that minimize its risk [33, 34].”
BackgroundWu, Y., Li, R., Zhang, Y., Long, T., Zhang, Q., & Li, M. (2022) · Biological Research For Nursing · doi:10.1177/10998004221115856 · Cited by 5
“The ADA reported in 2013 that greater attention must be focused on understanding which patients were at most risk for hypoglycemia (Seaquist et al., 2013).”
BackgroundLi, L., Lip, G. Y. H., Li, S., Adachi, J. D., Thabane, L., & Li, G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01567-9 · Cited by 5
“Furthermore, hypoglycemia was a common complication in diabetes and intensive HbA1c targets could increase the risk of hypoglycemia, especially for those treated with insulin [24, 25].”
BackgroundАнтонова, К. В., Лагода, О. В., & Tanashyan, M. М. (2022) · Diabetes Mellitus · doi:10.14341/dm12840 · Cited by 7
A glucose meter evaluation co-designed with both health professional and consumer input.
Thompson, H., Chan, H., Logan, F. J., Heenan, H. F., Taylor, L., Murray, C., Florkowski, C. M., FRAMPTON, C. M. A., & Lunt, H. (2013) · PubMed · Cited by 6
Arrhythmogenic effects of hypoglycemia in children and adolescents with type 1 diabetes mellitus
Лаптев, Д. Н., & Ryabykina, G. V. (2013) · Diabetes Mellitus · doi:10.14341/dm2013466-71 · Cited by 11
D’Netto, M. E., Murphy, C. V., Mitchell, A., & Dungan, K. M. (2015) · Hospital Practice · doi:10.1080/21548331.2016.1130584 · Cited by 6
“mia in ambulatory patients are problematic for use in the hospital [22] and more commonly, a threshold criterion of <40 mg/dl is used.”
MethodSetford, S. J., Grady, M., Mackintosh, S., Donald, R., & Levy, B. L. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818776668 · Cited by 5
Kallenbach, L., Shui, A. M., Cheng, W. Y., Fan, T., Hu, W., Zichlin, M. L., Duh, M. S., Ye, F., & LEVIN, P. A. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0261 · Cited by 6
Unger, J., Allison, D. C., Carlton, M., Lakkole, K., Lowe, D., Murphy, G., Panda, J. K., Sargın, M., Kaltoft, M. S., Treppendahl, M. B., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13682 · Cited by 4
Metadata
- Authors
- Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R.
- Affiliations
- University of Minnesota (US)
- The Frist Clinic, Nashville, Tennessee;
- Mid-America Diabetes Associates, Wichita, Kansas; the
- Washington University in St. Louis (US)
- University of Tennessee Health Science Center (US)
- Park Nicollet Clinic (US)
- University of Sheffield (GB)
- University of South Florida (US)
- Boston University (US)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Seaquist, Elizabeth R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1384-1395
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631867
- OpenAlex
- W2109416725
- Cited by
- 1,389
- References
- 141
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 62 · 2023: 66 · 2022: 92 · 2021: 127 · 2020: 119 · 2019: 149 · 2018: 148 · 2017: 151 · 2016: 129 · 2015: 129 · 2014: 92 · 2013: 33
- FWCI
- 100.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, diabetes mellitus, hypoglycemia definition, hypoglycemia prevention, long-term outcomes, patient counseling, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemia, Societies, Medical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.